Our present study revealed that tumors of mice receiving CIRT+HCQ‐treated pancreatic cancer cells were sensitive to anti‐CTLA4 mAb, whereas those receiving untreated control cells were resistant to it, indicating that CIRT might render cancer cells sensitive to Treg blockade. This evidence concerns the gene CTLA4 and cancer.